To determine whether these new Arf1-targeting compounds have the anti-HNSCC ability, we evaluated the viability of HN12 cells after exposure to γ-dipeptides 8–10 at a range dose from 0 to 20 μM. Here, ARF1 is linked to head and neck squamous cell carcinoma.